For 25 years, we have helped change what is possible in type 1 diabetes research.
Since 2001, TrialNet has brought together researchers, families, and participants in pursuit of a future without type 1 diabetes. New possibilities are now becoming reality through early detection, prevention research, newly diagnosed research, and the power of participation.
Longest-running international program for type 1 diabetes screening and prevention trials.
TrialNet has screened more than 250,000 individuals at risk for T1D.
Developed the widely adopted TrialNet ribbon explaining the stages and progression of T1D.
Studied more than 10 disease-modifying therapies across multiple stages of progression.
TrialNet research helped lead to the first FDA-approved drug to delay type 1 diabetes.
Published more than 300 peer-reviewed papers advancing T1D prevention and treatment.